Cargando…

Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future

The field of plasma medicine has seen substantial advances over the last decade, with applications developed for bacterial sterilisation, wound healing and cancer treatment. Low temperature plasmas (LTPs) are particularly suited for medical purposes since they are operated in the laboratory at atmos...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirst, Adam M., Frame, Fiona M., Arya, Manit, Maitland, Norman J., O’Connell, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875936/
https://www.ncbi.nlm.nih.gov/pubmed/26888782
http://dx.doi.org/10.1007/s13277-016-4911-7
_version_ 1782433162153951232
author Hirst, Adam M.
Frame, Fiona M.
Arya, Manit
Maitland, Norman J.
O’Connell, Deborah
author_facet Hirst, Adam M.
Frame, Fiona M.
Arya, Manit
Maitland, Norman J.
O’Connell, Deborah
author_sort Hirst, Adam M.
collection PubMed
description The field of plasma medicine has seen substantial advances over the last decade, with applications developed for bacterial sterilisation, wound healing and cancer treatment. Low temperature plasmas (LTPs) are particularly suited for medical purposes since they are operated in the laboratory at atmospheric pressure and room temperature, providing a rich source of reactive oxygen and nitrogen species (RONS). A great deal of research has been conducted into the role of reactive species in both the growth and treatment of cancer, where long-established radio- and chemo-therapies exploit their ability to induce potent cytopathic effects. In addition to producing a plethora of RONS, LTPs can also create strong electroporative fields. From an application perspective, it has been shown that LTPs can be applied precisely to a small target area. On this basis, LTPs have been proposed as a promising future strategy to accurately and effectively control and eradicate tumours. This review aims to evaluate the current state of the literature in the field of plasma oncology and highlight the potential for the use of LTPs in combination therapy. We also present novel data on the effect of LTPs on cancer stem cells, and speculatively outline how LTPs could circumvent treatment resistance encountered with existing therapeutics.
format Online
Article
Text
id pubmed-4875936
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-48759362016-07-06 Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future Hirst, Adam M. Frame, Fiona M. Arya, Manit Maitland, Norman J. O’Connell, Deborah Tumour Biol Review The field of plasma medicine has seen substantial advances over the last decade, with applications developed for bacterial sterilisation, wound healing and cancer treatment. Low temperature plasmas (LTPs) are particularly suited for medical purposes since they are operated in the laboratory at atmospheric pressure and room temperature, providing a rich source of reactive oxygen and nitrogen species (RONS). A great deal of research has been conducted into the role of reactive species in both the growth and treatment of cancer, where long-established radio- and chemo-therapies exploit their ability to induce potent cytopathic effects. In addition to producing a plethora of RONS, LTPs can also create strong electroporative fields. From an application perspective, it has been shown that LTPs can be applied precisely to a small target area. On this basis, LTPs have been proposed as a promising future strategy to accurately and effectively control and eradicate tumours. This review aims to evaluate the current state of the literature in the field of plasma oncology and highlight the potential for the use of LTPs in combination therapy. We also present novel data on the effect of LTPs on cancer stem cells, and speculatively outline how LTPs could circumvent treatment resistance encountered with existing therapeutics. Springer Netherlands 2016-02-18 /pmc/articles/PMC4875936/ /pubmed/26888782 http://dx.doi.org/10.1007/s13277-016-4911-7 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Hirst, Adam M.
Frame, Fiona M.
Arya, Manit
Maitland, Norman J.
O’Connell, Deborah
Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
title Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
title_full Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
title_fullStr Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
title_full_unstemmed Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
title_short Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
title_sort low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875936/
https://www.ncbi.nlm.nih.gov/pubmed/26888782
http://dx.doi.org/10.1007/s13277-016-4911-7
work_keys_str_mv AT hirstadamm lowtemperatureplasmasasemergingcancertherapeuticsthestateofplayandthoughtsforthefuture
AT framefionam lowtemperatureplasmasasemergingcancertherapeuticsthestateofplayandthoughtsforthefuture
AT aryamanit lowtemperatureplasmasasemergingcancertherapeuticsthestateofplayandthoughtsforthefuture
AT maitlandnormanj lowtemperatureplasmasasemergingcancertherapeuticsthestateofplayandthoughtsforthefuture
AT oconnelldeborah lowtemperatureplasmasasemergingcancertherapeuticsthestateofplayandthoughtsforthefuture